Are You Buying Gilead Sciences, Inc. for the Wrong Reason?
Gilead Sciences (NASDAQ: GILD) is up about 12% over the last week or so since Novartis (NYSE: NVS) got its chimeric antigen receptor T-cell (CAR-T) therapy Kymriah approved by the FDA.
That's just ridiculous for a couple of reasons:
The best-case scenario for Gilead wasn't an FDA approval of Kymriah, but a rejection based on some reason other than the fact that it was a CAR-T therapy.
Source: Fool.com
Novartis AG ADR Stock
€102.00
0.000%
Our community is currently high on Novartis AG ADR with 3 Buy predictions and 0 Sell predictions.
As a result the target price of 112 € shows a slightly positive potential of 9.8% compared to the current price of 102.0 € for Novartis AG ADR.
